These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 19217031)

  • 1. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
    Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
    Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3).
    Nassar A; Cohen C; Siddiqui M
    Diagn Cytopathol; 2009 Dec; 37(12):865-70. PubMed ID: 19530101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Image cytometric validation of breast carcinoma markers (ER, HER2 and MIB-1) using tissue microarrays: rabbit monoclonal vs. FDA-approved antibodies.
    Nassar A; Norton CM; Lawson D; Cohen C
    Anal Quant Cytol Histol; 2010 Aug; 32(4):192-200. PubMed ID: 21434519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and progesterone receptors in breast cancer: comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay.
    Cavaliere A; Bucciarelli E; Sidoni A; Bianchi G; Pietropaoli N; Ludovini V; Vitali R
    Cytometry; 1996 Sep; 26(3):204-8. PubMed ID: 8889392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
    Rhodes A; Sarson J; Assam EE; Dean SJ; Cribb EC; Parker A
    Am J Clin Pathol; 2010 Oct; 134(4):621-32. PubMed ID: 20855644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
    Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
    Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry.
    Rocha R; Nunes C; Rocha G; Oliveira F; Sanches F; Gobbi H
    Pathol Res Pract; 2008; 204(9):655-62. PubMed ID: 18565685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
    Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
    Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
    Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
    Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: comparison on cell block, needle-core, and tissue block preparations.
    Hanley KZ; Birdsong GG; Cohen C; Siddiqui MT
    Cancer; 2009 Aug; 117(4):279-88. PubMed ID: 19551847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue microarray-based immunohistochemical study can significantly underestimate the expression of HER2 and progesterone receptor in ductal carcinoma in situ of the breast.
    Lin Y; Hatem J; Wang J; Quinn A; Hicks D; Tang P
    Biotech Histochem; 2011 Oct; 86(5):345-50. PubMed ID: 20701550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative immunohistochemistry using the CAS 200/486 image analysis system in invasive breast carcinoma: a reproducibility study.
    Makkink-Nombrado SV; Baak JP; Schuurmans L; Theeuwes JW; van der Aa T
    Anal Cell Pathol; 1995 Apr; 8(3):227-45. PubMed ID: 7547496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
    Rocha RM; Nunes CB; Sanches FS; Rocha GF; Oliveira FN; Reis-Filho JS; Lambros MB; Gobbi H
    Rev Assoc Med Bras (1992); 2009; 55(2):163-8. PubMed ID: 19488652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
    Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
    J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience.
    Faratian D; Kay C; Robson T; Campbell FM; Grant M; Rea D; Bartlett JM
    Histopathology; 2009 Nov; 55(5):587-93. PubMed ID: 19912364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A comparative study of hormone receptors in breast cancer with quantitative immunocytochemistry and biochemistry].
    Marcot I; Migeon C; Parache RM; Marchal S; Virion JM
    Bull Cancer; 1997 Jun; 84(6):613-8. PubMed ID: 9295864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.